Publié 24 Avr. 2024
Appel à projets clos
The goals of the program are:
- to support the career development of outstanding EACR members in the early stage of their careers
- to train the next generation of scientists engaged in innovative research in areas where AstraZeneca has demonstrated leadership through its pipeline and research programs
- to build research collaborations between the EACR, institutions and AstraZeneca in core therapeutic areas to support development of the pipeline
Proposed research projects must:
- be basic and/or translational in nature. Translational research is preferred.
- have direct applicability and relevance to at least one of haematology, breast, lung, prostate, pancreatic, gastric, ovarian, liver, colorectal or paediatric cancer.
Projects should focus on one of the following research areas:
- Cell Therapy
- Immune modulating therapies
- Tumour drivers
- Mechanisms of resistance to therapy
- Mechanisms of sensitivity/resistance to PARP inhibitors and other DNA Damage Response inhibitors
- Novel approaches to drugging intractable targets
- Mechanisms of sensitivity and resistance to antibody drug conjugates
- Epigenetics
Deadline for submissions: April 24, 2024